Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00110
|
|||||
| Drug Name |
YM155
|
|||||
| Synonyms |
Sepantronium
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Breast cancer [ICD11: 2C60-2C6Z] | Phase 2 | [1] | |||
| Non hodgkin's lymphoma [ICD11: 2A8Z] | Phase 2 | [1] | ||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H19BrN4O3
|
|||||
| Canonical SMILES |
CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]
|
|||||
| InChI |
InChI=1S/C20H19N4O3.BrH/c1-13-23(9-10-27-2)17-18(24(13)12-14-11-21-7-8-22-14)20(26)16-6-4-3-5-15(16)19(17)25;/h3-8,11H,9-10,12H2,1-2H3;1H/q+1;/p-1
|
|||||
| InChIKey |
QBIYUDDJPRGKNJ-UHFFFAOYSA-M
|
|||||
| CAS Number |
CAS 781661-94-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 443.3 | Topological Polar Surface Area | 78 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 6 | |||
| PubChem CID | ||||||
| PubChem SID |
126671465
, 126731543
, 135264254
, 135626882
, 136367721
, 137060252
, 152258115
, 152344378
, 160646954
, 160671270
, 162133986
, 162202717
, 16258519
, 164023453
, 164194055
, 164834152
, 174530716
, 184811802
, 198972028
, 223401407
, 223681577
, 223704842
, 227016048
, 23368945
, 241383574
, 251971032
, 252160324
, 252216631
, 252451818
, 42257948
, 49684264
, 57376216
, 79265296
|
|||||
| ChEBI ID |
CHEBI:139608
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| OCT-2 | Transporter Info | Organic cation transporter 2 | Substrate | [2] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OCT-1 | Transporter Info | Km = 22.1 microM | Human embryonic kidney cells (HEK293)-OCT1 | [2] | |
| OCT-2 | Transporter Info | Km = 2.67 microM | Human embryonic kidney cells (HEK293)-OCT2 | [2] | ||
| References | ||||||
| 1 | ClinicalTrials.gov (NCT01007292) A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment | |||||
| 2 | Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.